Exploring the Impact of Digital Monitoring on Early Detection of Toxicities in HER2-Positive Breast Cancer Patients
Exploring the Impact of Digital Monitoring on Early Detection of Toxicities in HER2-Positive Breast Cancer Patients
The ongoing research project TOP-REAL aims to examine whether digital monitoring can facilitate the early detection of toxicities in patients with HER2-positive metastatic breast cancer. Conducted by the clinical research group Solti and supported by esteemed institutions in France and Germany, this international academic study addresses a crucial need in cancer treatment today.
Study Overview
TOP-REAL was recently introduced at the ESMO AI Digital Oncology 2026 congress, showcasing an innovative design that integrates digital tools into the monitoring process of patients. The primary goal is to evaluate whether earlier identification of toxicities can maintain the continuity of effective treatment regimens involving trastuzumab deruxtecan (T-DXd) and pertuzumab.
This study involves proactive monitoring methods, tapping into various technological advancements to keep track of patients’ symptoms and physiological changes beyond hospital visits. Such measures could potentially provide vital insights that would enable timely interventions, thus preventing toxicities from worsening.
Key Features of TOP-REAL
The framework of this study includes about 300 participants across 60 centers in Spain, France, and Germany. A unique aspect of the TOP-REAL study is its approach to include patient-reported outcomes through electronic platforms, continuous pulse oximetry, and data collection via smartwatches. This system also integrates alerts that could prompt earlier clinical evaluations.
The researchers emphasize the significance of understanding the impact of treatment on patients’ quality of life as they navigate through their cancer therapy. As Dr. Cristina Saura, the principal investigator of TOP-REAL, explained, the objective is to enhance not just the clinical outcomes but also the overall experience for the patients undergoing treatment.
Monitoring Toxicities in Real-Time
A growing concern in managing HER2-positive breast cancer is the toxicity associated with various treatment options. With treatment efficacy increasing, the management of these side effects becomes paramount to ensure patients can maintain their treatment regimens without adverse impacts on their daily lives. TOP-REAL particularly focuses on specific toxicities such as interstitial lung disease and treatment-related pneumonitis associated with T-DXd.
Continuous monitoring through pulse oximetry and periodic stress tests will aid in recognizing significant physiological shifts that could warrant immediate medical attention. This exploratory approach is transformative in navigating the complexities of cancer treatment and toxicity management.
Inclusion of Diverse Patient Profiles
TOP-REAL distinguishes itself by incorporating patient profiles that are often underrepresented in pivotal clinical trials. This includes patients with active brain metastases or those identified as having ECOG performance status 2. The intention is to develop a comprehensive understanding of treatment efficacy across a broader patient demographic closely resembling those found in actual clinical practice.
As Dr. Santiago Escrivà articulated, the findings from this study are expected to empower clinicians in effectively implementing trastuzumab deruxtecan and pertuzumab in real-world settings while optimizing toxicity management. By leveraging digital tools, healthcare providers aim to enhance the overall quality of life for patients.
Promising Outcomes and Future Directions
To evaluate the benefits of this approach, TOP-REAL will assess the time until the administration of subsequent anticancer therapies alongside measurements of quality of life via the EORTC QLQ-C30 survey. This comprehensive strategy aims to fill gaps in current research and provide actionable insights into how digital monitoring can translate into improved clinical care.
European collaboration is integral to this initiative, as it seeks not only to address toxicity management but also the feasibility of re-administering T-DXd in selected patients. The program promises to deliver significant findings, supplemented by analyses of tumor biopsies and blood samples, aimed at identifying potential biomarkers related to treatment response and toxicity.
In summary, the integration of a digital monitoring framework centered around patient needs within the TOP-REAL study positions it as a groundbreaking undertaking in the oncology field, ultimately contributing to a paradigm shift in how cancer care is delivered across different healthcare systems.
Conclusion
With support from Solti, Unicancer, and the West German Study Group, along with backing from renowned pharmaceutical entities, the TOP-REAL study emerges as a potential game-changer in the approach to monitoring and enhancing the quality of life for patients suffering from HER2-positive metastatic breast cancer. The study reflects a broader commitment to patient-centric care, integrating advances in technology with the realities of clinical practice.